Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen : Data from a Real-Life Setting
Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (-0.36, p < 0.0001) than in the RPV cohort (-0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (-14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Viruses - 15(2023), 7 vom: 23. Juli |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 03.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v15071612 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360151671 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360151671 | ||
| 003 | DE-627 | ||
| 005 | 20231226082412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v15071612 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360151671 | ||
| 035 | |a (NLM)37515298 | ||
| 035 | |a (PII)1612 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maggi, Paolo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen |b Data from a Real-Life Setting |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 03.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (-0.36, p < 0.0001) than in the RPV cohort (-0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (-14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ART-experienced | |
| 650 | 4 | |a HIV infection | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a doravirine | |
| 650 | 4 | |a hepatic safety | |
| 650 | 4 | |a metabolic safety | |
| 650 | 4 | |a rilpivirine | |
| 650 | 7 | |a Rilpivirine |2 NLM | |
| 650 | 7 | |a FI96A8X663 |2 NLM | |
| 650 | 7 | |a doravirine |2 NLM | |
| 650 | 7 | |a 913P6LK81M |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Transaminases |2 NLM | |
| 650 | 7 | |a EC 2.6.1.- |2 NLM | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 650 | 7 | |a Lipoproteins, LDL |2 NLM | |
| 700 | 1 | |a Ricci, Elena Delfina |e verfasserin |4 aut | |
| 700 | 1 | |a Martinelli, Canio Vito |e verfasserin |4 aut | |
| 700 | 1 | |a De Socio, Giuseppe Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Squillace, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Molteni, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Masiello, Addolorata |e verfasserin |4 aut | |
| 700 | 1 | |a Orofino, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Menzaghi, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Bellagamba, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Vichi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Celesia, Benedetto Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Madeddu, Giordano |e verfasserin |4 aut | |
| 700 | 1 | |a Pellicanò, Giovanni Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Carleo, Maria Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Cascio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Parisini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Taramasso, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Valsecchi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Calza, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Rusconi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Sarchi, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Martini, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Bargiacchi, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Falasca, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Cenderello, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Biagio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bonfanti, Paolo |e verfasserin |4 aut | |
| 700 | 0 | |a CISAI Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 15(2023), 7 vom: 23. Juli |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:7 |g day:23 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v15071612 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 7 |b 23 |c 07 | ||